NBIX

$NBIX

Neurocrine Biosciences, Inc.

Neuroscience-focused biotech developing treatments for neurological and endocrine disorders.

Healthcare
$156.59
-6.27 (-3.85%)
Day Range$156.31 - $163.46
Prev Close$162.86

NBIX key facts as of November 14, 2026

Latest AI research report
NBIX Outlook: Growth, Valuation and Catalysts (as of November 14, 2026)
StockAlpha report sentiment
Bullish (as of November 14, 2026)
Analyst consensus
Strong Buy (4 Strong Buy, 21 Buy, 4 Hold, 0 Sell, 0 Strong Sell) (as of November 1, 2026)
Analyst price target
$203.41 mean (range $165.00 to $225.00) (as of November 20, 2026)
Sector
Healthcare
Analyst Rating
Strong Buy
25 Buy / 4 Hold / 0 Sell
Price Target
$203.41
29.9% upside
Subscribers
0
Tracking this ticker
Latest Report

Analysis from Nov 14, 2026

BULLISH

NBIX Outlook: Growth, Valuation and Catalysts

Neurocrine combines strong reported revenue growth and a sharp latest-quarter EPS beat with a favorable analyst consensus. Its valuation, uneven earnings-growth indicators and reliance on commercial execution remain important counterweights.

Nov 14, 2026

NBIX FAQ

What is StockAlpha's latest view on NBIX?

StockAlpha's latest AI research report on Neurocrine Biosciences, Inc. (NBIX), "NBIX Outlook: Growth, Valuation and Catalysts", was published on November 14, 2026 and rates the overall sentiment as bullish. Neurocrine combines strong reported revenue growth and a sharp latest-quarter EPS beat with a favorable analyst consensus. Its valuation, uneven earnings-growth indicators and reliance on commercial execution remain important counterweights.

When was the NBIX research last updated?

The most recent NBIX report was published on November 14, 2026.

What do analysts expect for NBIX?

As of November 1, 2026, the analyst consensus on NBIX is Strong Buy (4 Strong Buy, 21 Buy, 4 Hold, 0 Sell, 0 Strong Sell). As of November 20, 2026, the analyst price target is $203.41 mean (range $165.00 to $225.00).

Is this NBIX research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring